These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

400 related items for PubMed ID: 27629740

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. [Expression of GLUT-1, p63 and DNA-Pkcs in serous ovarian tumors and their significance].
    Shao SL, Cai Y, Wang QH, Yan LJ, Zhao XY, Wang LX.
    Zhonghua Zhong Liu Za Zhi; 2007 Sep; 29(9):697-700. PubMed ID: 18246802
    [Abstract] [Full Text] [Related]

  • 3. [Expression and significance of GLUT-1 and DNA-PKcs in serous ovarian tumors].
    Cai Y, Shao SL, Wang QH, Yan LJ, Wang XY, Wang LX.
    Ai Zheng; 2007 Nov; 26(11):1188-93. PubMed ID: 17991316
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Relationship between P53 Protein Expression and Prognosis of Advanced Ovarian Serous Adenocarcinoma].
    Zuo J, Song Y, Li Z, Wu LY.
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2016 Apr; 38(2):169-74. PubMed ID: 27181893
    [Abstract] [Full Text] [Related]

  • 6. [Expression and significance of microRNAs in the p53 pathway in ovarian cancer cells and serous ovarian cancer tissues].
    Zhang Q, He XJ, Ma LP, Li N, Yang J, Cheng YX, Cui H.
    Zhonghua Zhong Liu Za Zhi; 2011 Dec; 33(12):885-90. PubMed ID: 22340095
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Molecular characterization of 103 ovarian serous and mucinous tumors.
    Vereczkey I, Serester O, Dobos J, Gallai M, Szakács O, Szentirmay Z, Tóth E.
    Pathol Oncol Res; 2011 Sep; 17(3):551-9. PubMed ID: 21136228
    [Abstract] [Full Text] [Related]

  • 9. The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients.
    Gayarre J, Kamieniak MM, Cazorla-Jiménez A, Muñoz-Repeto I, Borrego S, García-Donas J, Hernando S, Robles-Díaz L, García-Bueno JM, Ramón Y Cajal T, Hernández-Agudo E, Heredia Soto V, Márquez-Rodas I, Echarri MJ, Lacambra-Calvet C, Sáez R, Cusidó M, Redondo A, Paz-Ares L, Hardisson D, Mendiola M, Palacios J, Benítez J, García MJ.
    J Gynecol Oncol; 2016 Jan; 27(1):e7. PubMed ID: 26463438
    [Abstract] [Full Text] [Related]

  • 10. Combination of serum hCG beta and p53 tissue expression defines distinct subgroups of serous ovarian carcinoma.
    Vartiainen J, Lassus H, Lehtovirta P, Finne P, Alfthan H, Butzow R, Stenman UH.
    Int J Cancer; 2008 May 01; 122(9):2125-9. PubMed ID: 18098286
    [Abstract] [Full Text] [Related]

  • 11. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL, Shen DH, Xue WC, Li Y, Yu YZ.
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr 01; 42(4):227-32. PubMed ID: 17631760
    [Abstract] [Full Text] [Related]

  • 12. THE PROGNOSTIC SIGNIFICANCE OF P53, BCL2 AND MIB1 EXPRESSIONS RELATED WITH OTHER CLINICOPATHOLOGICAL VARIABLES IN SEROUS OVARIAN CARCINOMAS. A CLINICOPATHOLOGICAL STUDY IN PERITONEAL FLUIDS.
    Kalogeraki A, Tamiolakis D, Matalliotaki C, Karvela-Kalogeraki I, Karvelas-Kalogerakis M, Segredakis J, Sinatkas V, Matalliotakis I.
    Rev Med Chir Soc Med Nat Iasi; 2015 Apr 01; 119(2):454-60. PubMed ID: 26204652
    [Abstract] [Full Text] [Related]

  • 13. Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high-grade serous carcinoma.
    Chiesa-Vottero AG, Malpica A, Deavers MT, Broaddus R, Nuovo GJ, Silva EG.
    Int J Gynecol Pathol; 2007 Jul 01; 26(3):328-33. PubMed ID: 17581420
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of p53 induces invasion of serous borderline ovarian tumor cells by accentuating PI3K/Akt-mediated suppression of E-cadherin.
    Cheng JC, Auersperg N, Leung PC.
    Oncogene; 2011 Mar 03; 30(9):1020-31. PubMed ID: 20972462
    [Abstract] [Full Text] [Related]

  • 15. [Morphologic changes of fallopian tubal epithelium in ovarian serous tumors].
    Wen J, Shi JL, Shen DH, Chen YX, Song QJ.
    Zhonghua Bing Li Xue Za Zhi; 2012 Jul 03; 41(7):433-7. PubMed ID: 22932451
    [Abstract] [Full Text] [Related]

  • 16. Tissue array analysis of expression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer.
    Ouellet V, Guyot MC, Le Page C, Filali-Mouhim A, Lussier C, Tonin PN, Provencher DM, Mes-Masson AM.
    Int J Cancer; 2006 Aug 01; 119(3):599-607. PubMed ID: 16572426
    [Abstract] [Full Text] [Related]

  • 17. Expression of p53, p21WAF1/CIP1, p16INK4A and Ki-67 proteins in serous ovarian tumors.
    Buchynska LG, Nesina IP, Yurchenko NP, Bilyk OO, Grinkevych VN, Svintitsky VS.
    Exp Oncol; 2007 Mar 01; 29(1):49-53. PubMed ID: 17431389
    [Abstract] [Full Text] [Related]

  • 18. ELF5 in epithelial ovarian carcinoma tissues and biological behavior in ovarian carcinoma cells.
    Yan H, Qiu L, Xie X, Yang H, Liu Y, Lin X, Huang H.
    Oncol Rep; 2017 Mar 01; 37(3):1412-1418. PubMed ID: 28184931
    [Abstract] [Full Text] [Related]

  • 19. Targeted Genomic Sequencing Reveals Novel TP53 In-frame Deletion Mutations Leading to p53 Overexpression in High-grade Serous Tubo-ovarian Carcinoma.
    Jung YY, Woo HY, Kim HS.
    Anticancer Res; 2019 Jun 01; 39(6):2883-2889. PubMed ID: 31177126
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.